PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
31385617-0	2020	Effects of Maribavir on P-Glycoprotein and CYP2D6 in Healthy Volunteers.	maribavir	11-20	ATP binding cassette subfamily B member 1	Homo sapiens	24-38
31385617-12	2020	Maribavir inhibited P-gp activity but did not affect CYP2D6 activity.	maribavir	0-9	ATP binding cassette subfamily B member 1	Homo sapiens	20-24
31385617-13	2020	Maribavir"s effect on the pharmacokinetics of P-gp substrates should be evaluated individually, and caution should be exercised with P-gp substrates with narrow therapeutic windows.	maribavir	0-9	ATP binding cassette subfamily B member 1	Homo sapiens	46-50
29458130-8	2018	Our previous studies demonstrated the importance of p21 in the antiviral activity of the HCMV kinase inhibitor, maribavir.	maribavir	112-121	H3 histone pseudogene 16	Homo sapiens	52-55
31654672-3	2019	Using the Chou-Talalay method, we found that in-vitro combination of artemisone with cidofovir, brincidofovir, or with the HCMV UL97 inhibitor maribavir resulted in antiviral synergism and the combination of artemisone with ganciclovir or with the viral terminase inhibitors letermovir and BDCRB resulted in moderate synergism.	maribavir	143-152	tegument serine/threonine protein kinase	Human betaherpesvirus 5	128-132
31478398-4	2019	An investigational agent, maribavir, exerts its anti-CMV effect through UL97 inhibition, and its safety profile is under clinical evaluation.	maribavir	26-35	tegument serine/threonine protein kinase	Human betaherpesvirus 5	72-76
25339763-7	2015	Notably, treatment of infected cells with the UL97 inhibitor maribavir or infection with a UL97 mutant led to a punctate rather than a continuous distribution of the NEC at the nuclear rim.	maribavir	61-70	tegument serine/threonine protein kinase	Human betaherpesvirus 5	46-50
25339763-8	2015	Alanine substitutions in both UL50-S216 and UL53-S19 resulted in a punctate distribution of the NEC in infected cells and also decreased virus production and nuclear egress in the absence of maribavir.	maribavir	191-200	nuclear egress membrane protein	Human betaherpesvirus 5	30-34
24070820-0	2013	Inhibition of cellular STAT3 synergizes with the cytomegalovirus kinase inhibitor maribavir to disrupt infection.	maribavir	82-91	signal transducer and activator of transcription 3	Homo sapiens	23-28
24522923-10	2014	IMPORTANCE: The HCMV UL97 kinase performs important functions in viral replication that are targeted by the antiviral drug maribavir.	maribavir	123-132	tegument serine/threonine protein kinase	Human betaherpesvirus 5	21-25
21906628-1	2011	Select mutations in the human cytomegalovirus (HCMV) gene UL27 confer low-grade resistance to the HCMV UL97 kinase inhibitor maribavir (MBV).	maribavir	125-134	protein UL27	Human betaherpesvirus 5	58-62
21906628-1	2011	Select mutations in the human cytomegalovirus (HCMV) gene UL27 confer low-grade resistance to the HCMV UL97 kinase inhibitor maribavir (MBV).	maribavir	125-134	tegument serine/threonine protein kinase	Human betaherpesvirus 5	103-107
21429239-0	2010	The effects of maribavir on the autophosphorylation of ganciclovir resistant mutants of the cytomegalovirus UL97 protein.	maribavir	15-24	tegument serine/threonine protein kinase	Human betaherpesvirus 5	108-112
21570426-0	2011	Genotypic characterization of human cytomegalovirus UL97 phosphotransferase natural polymorphism in the era of ganciclovir and maribavir.	maribavir	127-136	tegument serine/threonine protein kinase	Human betaherpesvirus 5	52-56
21570426-1	2011	The molecular mechanisms of human cytomegalovirus (CMV) resistance to both ganciclovir and maribavir reported so far rely predominantly on the presence of mutations within UL97 phosphotransferase.	maribavir	91-100	tegument serine/threonine protein kinase	Human betaherpesvirus 5	172-176
21570426-7	2011	Together with all previous results reported in the literature, a new map of UL97 phosphotransferase natural polymorphism could be settled in the era of ganciclovir and maribavir.	maribavir	168-177	tegument serine/threonine protein kinase	Human betaherpesvirus 5	76-80
21320693-7	2011	Consequently, either increasing p21(Waf1/Cip1) expression or decreasing Tip60 levels improved the antiviral activity of the HCMV kinase inhibitor maribavir.	maribavir	146-155	cyclin dependent kinase inhibitor 1A	Homo sapiens	32-35
21320693-7	2011	Consequently, either increasing p21(Waf1/Cip1) expression or decreasing Tip60 levels improved the antiviral activity of the HCMV kinase inhibitor maribavir.	maribavir	146-155	cyclin dependent kinase inhibitor 1A	Homo sapiens	36-40
21320693-7	2011	Consequently, either increasing p21(Waf1/Cip1) expression or decreasing Tip60 levels improved the antiviral activity of the HCMV kinase inhibitor maribavir.	maribavir	146-155	cyclin dependent kinase inhibitor 1A	Homo sapiens	41-45
21320693-7	2011	Consequently, either increasing p21(Waf1/Cip1) expression or decreasing Tip60 levels improved the antiviral activity of the HCMV kinase inhibitor maribavir.	maribavir	146-155	lysine acetyltransferase 5	Homo sapiens	72-77
21429239-1	2010	BACKGROUND: The UL97 protein kinase of human cytomegalovirus phosphorylates the antiviral drug ganciclovir and is the target of maribavir action.	maribavir	128-137	tegument serine/threonine protein kinase	Human betaherpesvirus 5	16-20
21429239-2	2010	A detailed enzyme kinetic analysis of maribavir on the various enzymatic functions of wild type and ganciclovir resistant forms of UL97 is required.	maribavir	38-47	tegument serine/threonine protein kinase	Human betaherpesvirus 5	131-135
21429239-3	2010	METHODS: Wild type and site directed mutant forms of the human cytomegalovirus UL97 gene product were expressed using recombinant baculoviruses and the purified products used to assess the effects of maribavir on the ganciclovir (GCV) kinase and protein kinase (PK) activities.	maribavir	200-209	tegument serine/threonine protein kinase	Human betaherpesvirus 5	79-83
21429239-8	2010	DISCUSSION: Maribavir is a potent competitive inhibitor of the UL97 protein kinase function and shows increased activity against the M460I GCV-resistant mutant which may impact on the management of GCV drug resistance in patients.	maribavir	12-21	tegument serine/threonine protein kinase	Human betaherpesvirus 5	63-67
19704169-2	2009	Maribavir is a new anti-HCMV drug that targets nuclear egress through direct inhibition of the HCMV serine-threonine kinase, UL97 protein (pUL97).	maribavir	0-9	tegument serine/threonine protein kinase	Human betaherpesvirus 5	125-129
19434630-0	2009	Function of human cytomegalovirus UL97 kinase in viral infection and its inhibition by maribavir.	maribavir	87-96	tegument serine/threonine protein kinase	Human betaherpesvirus 5	34-38
19434630-2	2009	The UL97 kinase null phenotype is therefore complex, as is the mechanism of action of maribavir, a highly specific inhibitor of its enzymatic activity.	maribavir	86-95	tegument serine/threonine protein kinase	Human betaherpesvirus 5	4-8
19159461-0	2009	Conserved retinoblastoma protein-binding motif in human cytomegalovirus UL97 kinase minimally impacts viral replication but affects susceptibility to maribavir.	maribavir	150-159	tegument serine/threonine protein kinase	Human betaherpesvirus 5	72-76
19159461-3	2009	Their susceptibility to the specific UL97 kinase inhibitor, maribavir, was also examined.	maribavir	60-69	tegument serine/threonine protein kinase	Human betaherpesvirus 5	37-41
19165338-4	2009	Transient treatment of HCMV-infected cells with maribavir, an inhibitor of UL97 kinase activity, reduced lamin A/C phosphorylation by approximately 50%, consistent with UL97 directly phosphorylating lamin A/C during HCMV replication.	maribavir	48-57	tegument serine/threonine protein kinase	Human betaherpesvirus 5	75-79
19165338-4	2009	Transient treatment of HCMV-infected cells with maribavir, an inhibitor of UL97 kinase activity, reduced lamin A/C phosphorylation by approximately 50%, consistent with UL97 directly phosphorylating lamin A/C during HCMV replication.	maribavir	48-57	lamin A/C	Homo sapiens	105-114
19165338-4	2009	Transient treatment of HCMV-infected cells with maribavir, an inhibitor of UL97 kinase activity, reduced lamin A/C phosphorylation by approximately 50%, consistent with UL97 directly phosphorylating lamin A/C during HCMV replication.	maribavir	48-57	tegument serine/threonine protein kinase	Human betaherpesvirus 5	169-173
19165338-4	2009	Transient treatment of HCMV-infected cells with maribavir, an inhibitor of UL97 kinase activity, reduced lamin A/C phosphorylation by approximately 50%, consistent with UL97 directly phosphorylating lamin A/C during HCMV replication.	maribavir	48-57	lamin A/C	Homo sapiens	199-208
18316526-2	2008	The main objective of this study was to assess the effects of oral ketoconazole, a potent inhibitor of the cytochrome P450 3A4 (CYP3A4) isoenzyme, on the pharmacokinetics of maribavir.	maribavir	174-183	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	107-126
18325607-0	2008	Expression of the human cytomegalovirus UL97 gene in a chimeric guinea pig cytomegalovirus (GPCMV) results in viable virus with increased susceptibility to ganciclovir and maribavir.	maribavir	172-181	tegument serine/threonine protein kinase	Human betaherpesvirus 5	40-44
18325607-10	2008	Additionally, GPCMV::UL97 exhibited improved susceptibility to another antiviral undergoing clinical trials, maribavir (MBV; benzimidazole riboside 1263W94), which also acts through UL97.	maribavir	109-118	tegument serine/threonine protein kinase	Human betaherpesvirus 5	21-25
18325607-10	2008	Additionally, GPCMV::UL97 exhibited improved susceptibility to another antiviral undergoing clinical trials, maribavir (MBV; benzimidazole riboside 1263W94), which also acts through UL97.	maribavir	109-118	tegument serine/threonine protein kinase	Human betaherpesvirus 5	182-186
18316526-2	2008	The main objective of this study was to assess the effects of oral ketoconazole, a potent inhibitor of the cytochrome P450 3A4 (CYP3A4) isoenzyme, on the pharmacokinetics of maribavir.	maribavir	174-183	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	128-134
18316526-8	2008	Based on the assumption of complete inhibition of CYP3A4 activity, CYP3A4 is responsible for 35% of the overall clearance of maribavir.	maribavir	125-134	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	50-56
18316526-8	2008	Based on the assumption of complete inhibition of CYP3A4 activity, CYP3A4 is responsible for 35% of the overall clearance of maribavir.	maribavir	125-134	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	67-73
17206862-6	2007	Broad inhibition of cell cycle-regulated kinases (Cdk1/Cdk2/Cdk5/Cdk9) with indirubin-3"-monoxime substantially decreases viral yields and synergizes with the viral UL97 kinase inhibitor, maribavir.	maribavir	188-197	cyclin dependent kinase 1	Homo sapiens	50-54
18321963-7	2008	We concluded from these studies that both UL97 kinase activity and the LxCxE RB binding motif are required for the phosphorylation and stabilization of RB in infected cells and that this effect can be antagonized by the antiviral drug maribavir.	maribavir	235-244	tegument serine/threonine protein kinase	Human betaherpesvirus 5	42-46
17206862-6	2007	Broad inhibition of cell cycle-regulated kinases (Cdk1/Cdk2/Cdk5/Cdk9) with indirubin-3"-monoxime substantially decreases viral yields and synergizes with the viral UL97 kinase inhibitor, maribavir.	maribavir	188-197	cyclin dependent kinase 2	Homo sapiens	55-59
17206862-6	2007	Broad inhibition of cell cycle-regulated kinases (Cdk1/Cdk2/Cdk5/Cdk9) with indirubin-3"-monoxime substantially decreases viral yields and synergizes with the viral UL97 kinase inhibitor, maribavir.	maribavir	188-197	cyclin dependent kinase 5	Homo sapiens	60-64
17206862-6	2007	Broad inhibition of cell cycle-regulated kinases (Cdk1/Cdk2/Cdk5/Cdk9) with indirubin-3"-monoxime substantially decreases viral yields and synergizes with the viral UL97 kinase inhibitor, maribavir.	maribavir	188-197	cyclin dependent kinase 9	Homo sapiens	65-69
15194788-0	2004	Mutations in the human cytomegalovirus UL27 gene that confer resistance to maribavir.	maribavir	75-84	protein UL27	Human betaherpesvirus 5	39-43
16565170-3	2006	Here, we report the identification of two enzymes, 8-oxoguanine DNA glycosylase (OGG1) and N-methylpurine DNA glycosylase (MPG), that catalyze N-glycosidic bond cleavage of BDCRB and its 2-chloro homolog, 2,5,6-trichloro-1-(beta-D-ribofuranosyl)benzimidazole, but not maribavir.	maribavir	268-277	8-oxoguanine DNA glycosylase	Homo sapiens	51-79
16565170-3	2006	Here, we report the identification of two enzymes, 8-oxoguanine DNA glycosylase (OGG1) and N-methylpurine DNA glycosylase (MPG), that catalyze N-glycosidic bond cleavage of BDCRB and its 2-chloro homolog, 2,5,6-trichloro-1-(beta-D-ribofuranosyl)benzimidazole, but not maribavir.	maribavir	268-277	8-oxoguanine DNA glycosylase	Homo sapiens	81-85
16565170-3	2006	Here, we report the identification of two enzymes, 8-oxoguanine DNA glycosylase (OGG1) and N-methylpurine DNA glycosylase (MPG), that catalyze N-glycosidic bond cleavage of BDCRB and its 2-chloro homolog, 2,5,6-trichloro-1-(beta-D-ribofuranosyl)benzimidazole, but not maribavir.	maribavir	268-277	N-methylpurine DNA glycosylase	Homo sapiens	91-121
16565170-3	2006	Here, we report the identification of two enzymes, 8-oxoguanine DNA glycosylase (OGG1) and N-methylpurine DNA glycosylase (MPG), that catalyze N-glycosidic bond cleavage of BDCRB and its 2-chloro homolog, 2,5,6-trichloro-1-(beta-D-ribofuranosyl)benzimidazole, but not maribavir.	maribavir	268-277	N-methylpurine DNA glycosylase	Homo sapiens	123-126
16565170-6	2006	These studies showed that OGG1 was not able to bind a negative control, guanosine, yet BDCRB and maribavir were stabilized through interactions with various binding site residues, including Phe319, His270, Ser320, and Asn149.	maribavir	97-106	8-oxoguanine DNA glycosylase	Homo sapiens	26-30
16569820-2	2006	The pharmacokinetics and safety of maribavir and the effects of maribavir on the activities of cytochrome P450 (CYP) 1A2, CYP 2C9, CYP 2C19, CYP 2D6, CYP 3A, N-acetyltransferase-2 (NAT-2), and xanthine oxidase (XO) were evaluated in a randomized, double-blind, placebo-controlled study.	maribavir	64-73	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	95-120
16571131-1	2006	Inhibition of the human cytomegalovirus UL97 kinase by maribavir is thought to be responsible for the antiviral activity of this compound.	maribavir	55-64	tegument serine/threonine protein kinase	Human betaherpesvirus 5	40-44
16571131-2	2006	Some mutations that confer resistance to maribavir map to UL97, however additional mutations that also confer resistance to the drug were mapped to UL27.	maribavir	41-50	tegument serine/threonine protein kinase	Human betaherpesvirus 5	58-62
15194788-8	2004	Viable UL27 deletion mutants were created by recombination and showed slight growth attenuation and maribavir resistance in cell culture.	maribavir	100-109	protein UL27	Human betaherpesvirus 5	7-11
15194788-9	2004	Marker transfer experiments confirmed that UL27 mutations conferred maribavir resistance.	maribavir	68-77	protein UL27	Human betaherpesvirus 5	43-47
15105156-0	2004	Effects of maribavir and selected indolocarbazoles on Epstein-Barr virus protein kinase BGLF4 and on viral lytic replication.	maribavir	11-20	tegument serine/threonine protein kinase	Human gammaherpesvirus 4	88-93
14557635-11	2003	Sequencing identified a single coding mutation in ORF UL27 (Leu335Pro) as the one responsible for resistance to maribavir.	maribavir	112-121	protein UL27	Human betaherpesvirus 5	54-58
14557635-12	2003	These results establish that UL27 is either directly or indirectly involved in the mechanism of action of maribavir.	maribavir	106-115	protein UL27	Human betaherpesvirus 5	29-33
12502806-1	2003	Human cytomegalovirus encodes an unusual protein kinase, UL97, that activates the established antiviral drug ganciclovir and is specifically inhibited by a new antiviral drug, maribavir.	maribavir	176-185	tegument serine/threonine protein kinase	Human betaherpesvirus 5	57-61
12829811-5	2003	This phosphorylation occurred on serine and threonine residues and was sensitive to inhibition by maribavir and to a mutation that inactivates UL97 catalytic activity.	maribavir	98-107	tegument serine/threonine protein kinase	Human betaherpesvirus 5	143-147
12048183-7	2002	Phosphorylation of the Ser-38 peptide by UL97 occurred on Ser-38 and was specifically sensitive to maribavir, whereas phosphorylation of this peptide by cAMP-dependent protein kinase occurred on Ser-36.	maribavir	99-108	tegument serine/threonine protein kinase	Human betaherpesvirus 5	41-45
12121907-10	2002	Metabolism of 1263W94 to its primary metabolite, an N-dealkylated analog, appeared to be mediated via the isozyme CYP3A4 in humans.	maribavir	14-21	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	114-120
35490740-5	2022	LTV was also effective against recombinant HCMV harboring UL97 mutations conferring resistance to maribavir.	maribavir	98-107	tegument serine/threonine protein kinase	Human betaherpesvirus 5	58-62